Protocol Ledger

NCT06568237 · Phase II · ACTIVE NOT RECRUITING

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

Interventional Phase II clinical trial protocol NCT06568237 sponsored by Teva Pharmaceutical in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-02 Enrollment: 349 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06568237
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)349 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06568237
Protocol FieldVerified Registry Value
NCT IdentifierNCT06568237
Consolidated Lead SponsorTeva Pharmaceutical
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment349 participants (ACTUAL)
Registered Start Date2024-10-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI